TIAA CREF Investment Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

TIAA CREF Investment Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$6.79M	Sell	303,258 -380,737	-56%	-$8.19M	﹤0.01%	1262
2018 Q4	$12.4M	Buy	683,995 +403,234	+144%	+$6.33M	0.01%	852
2018 Q3	$5.08M	Buy	280,761 +208,720	+290%	+$2.47M	﹤0.01%	1558
2018 Q2	$717K	Buy	72,041 +26,600	+59%	+$184K	﹤0.01%	2633
2018 Q1	$241K	Buy	45,441 +16,147	+55%	+$115K	﹤0.01%	2951
2017 Q4	$249K	Sell	29,294 -1,977	-6%	-$24.3K	﹤0.01%	2978
2017 Q3	$457K	Hold	31,271	–	–	﹤0.01%	2864
2017 Q2	$586K	Buy	31,271 +23,434	+299%	+$529K	﹤0.01%	2789
2017 Q1	$167K	Buy	7,837 +3,859	+97%	+$73.8K	﹤0.01%	3015
2016 Q4	$60K	Buy	+3,978	New	+$54.1K	﹤0.01%	3100

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MMPI

Morgenthaler Management Partners IX Portola Valley, California $22.6M AUM

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TIAA CREF Investment Management's RARX Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Ra Pharmaceuticals, Inc. Common Stock (RARX) stake by 56% in Q1 2019, selling an estimated $8.19M and leaving 303,258 shares worth $6.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1262.

TIAA CREF Investment Management first reported a position in RARX in Q4 2016 and has held it in 10 quarters since. The position peaked at $12.4M in Q4 2018. 124 funds tracked by Wall St. Rank hold RARX as of Q1 2019.

TIAA CREF Investment Management held 303,258 shares of Ra Pharmaceuticals, Inc. Common Stock worth $6.79M as of Q1 2019.
TIAA CREF Investment Management sold 380,737 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2019, an estimated $8.19M.
Ra Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1262 holding.
TIAA CREF Investment Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and has held it in 10 quarters since.
TIAA CREF Investment Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $12.4M in Q4 2018.
124 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.